Femme et Homme
- | Pays :
- France
- | Organes : -
- | Spécialités : -
Extrait
The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer.
Critère d'inclusion
- Breast Neoplasms ,Stomach Neoplasms